W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

21 August, 2024

Opinion of the President – rehabilitation program for residents of Gozdnica Municipality

21 August, 2024

Opinion of the President – Health Rehabilitation and Promotion of Physical Activity of Residents of the Municipality of Rybno for 2024-2026

16 August, 2024

Communication of the meeting of Transparency Council No. 34/2024 on 12 August 2024

16 August, 2024

Opinion of the President on the legitimacy of changes to the B.75 drug program

13 August, 2024

The Transparency Council meeting 35/2024 on 19 August 2024

12 August, 2024

Recommendation of the President – Kuvan (sapropterin dihydrochloride)

09 August, 2024

Recommendation of the President – Ultomiris (ravulizumab)

09 August, 2024

Recommendation of the President – Omvoh (mirikizumab)

09 August, 2024

Recommendation of the President – Zolgensma (onasemnogene abeparvovec)

09 August, 2024

Recommendation of the President – Ayvakyt (avapritinib)

08 August, 2024

Opinion of the Transparency Council – active substance sulfasalazinum

08 August, 2024

Opinion of the Transparency Council – active substance octreotidum

08 August, 2024

Opinion of the Transparency Council – active substance lanreotidum

08 August, 2024

Position of the Transparency Council – Kuvan (sapropterin)

08 August, 2024

Position of the Transparency Council – Ultomiris (ravulizumab)

08 August, 2024

Position of the Transparency Council – Omvoh (mirikizumab)

08 August, 2024

Position of the Transparency Council – Zolgensma (onasemnogene abeparvovec)

08 August, 2024

Position of the Transparency Council – Ayvakyt (avapritinib)

08 August, 2024

Communication of the meeting of Transparency Council No. 33/2024 on 5 August 2024

08 August, 2024

The Transparency Council meeting 34/2024 on 12 August 2024

02 August, 2024

Communication – TLI effectiveness evaluation report

02 August, 2024

Recommendation of the President – Gyroscopic stereotactic teleradiotherapy (TSZ) using a novel ZAP-X device

02 August, 2024

Recommendation of the President – Daraprim (pyrimethamine)

01 August, 2024

Opinion of the Transparency Council – doxazosinum (4mg)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑